SUGAM is the official CDSCO license application portal. It is a single-window online system for regulatory submissions. It ensures faster approvals and clear digital tracking of submissions. Central Drugs Standard Control Organization (CDSCO) has announced a new SUGAM portal application rejection rule. Applicants that fail to respond to regulatory queries within 90 days of the first reminder will have their application rejected.
What is SUGAM?
SUGAM is the official, single-window online portal launched by the Central Drugs Standard Control Organization of India. It aims to facilitate electronic submission and processing of applications for drugs, medical devices, cosmetics, and clinical trials. SUGAM is the online e‑governance portal that allows pharmaceutical companies, medical device manufacturers, cosmetics companies, and importers to apply for approvals, licenses, and permissions digitally. It streamlines submissions for manufacturing, import, and clinical trials, thereby promoting transparency and faster regulatory processing. Thus, SUGAM has the following functions:
- Apply for manufacturing and import licenses for drugs, medical devices, and cosmetics
- Submit clinical trial applications
- Upload formulation data and biologicals (vaccines, r-DNA) applications
- Request batch release certificates for vaccines
- Manage post-approval changes
Thus, CDSCO SUGAM portal has reduced manual paperwork and delays as well as strengthened regulatory oversight and compliance. It promotes transparency, accountability, and efficiency. Thus, for companies, it ensures faster approvals and clear digital tracking of submissions. For regulators, it helps CDSCO manage large volumes of applications and reduce backlogs. For healthcare system, it supports timely introduction of new drugs, devices, and vaccines into the Indian market. Hence, SUGAM is India’s digital gateway for drug and device regulation, thereby making compliance more efficient and transparent for both industry and regulators.
CDSCO introduces new 90-day SUGAM portal application rejection rule
CDSCO has introduced a new rule that any application submitted through the SUGAM portal will be automatically rejected if applicants fail to respond to regulatory queries within 90 days of the first reminder. The system issues three reminders at 30‑day intervals, and if no reply is received after the third, the application is discarded. This measure, effective from January 16, 2026, is designed to clear a backlog of submissions, some pending for years. It applies to drugs, medical devices, and IVDs. Additionally, CDSCO has introduced a free pre‑filing consultation facility for medical devices (excluding IVDs) to help manufacturers confirm risk classification before filing. The aim is to reduce misclassification disputes and streamline approvals.
Key highlights of the 90-day SUGAM portal application rejection rule
- Automatic rejection timeline: Any application will be rejected if regulatory queries remain unanswered for 90 days after the first reminder.
- Structured reminder system: First reminder when the CDSCO query is raised. A second reminder will be sent after 30 days. A third reminder will be sent after another 30 days. If still no response is received within 30 days of the 3rd reminder, the application will be discarded.
- Effective date: The rule was announced on January 16, 2026.
- Backlog clearance: Applications pending for over 2 years with three reminders must respond by February 14, 2026, or face rejection.
- Scope: This 90-day SUGAM portal application rejection rule applies to drugs, medical devices, and IVDs applications submitted via the SUGAM portal.
Pre-filing consultation facility
In addition to the 90-day SUGAM portal application rejection rule, the CDSCO has introduced a pre-filing consultation facility to guide CDSCO license applicants. The pre-filing consultation facility introduced by CDSCO is a structured support mechanism designed to help medical device manufacturers and importers avoid costly missteps before formally submitting applications on the SUGAM portal.
The pre-filing consultation facility is available only for medical devices and not IVDs. It applies to both domestic manufacturers and importers. The service will be offered free of charge.
Purpose
- To clarify risk classification of medical devices (Class A–D) before filing of the CDSCO medical device license application. This facility will be especially useful for Class A and B devices, where classification inconsistencies affect fees, requirements, and timelines.
- To prevent misclassification disputes that can lead to delays, incorrect fees, or rejection.
- To streamline regulatory submissions by ensuring applicants start with the correct pathway.
The applicants are required to submit a basic dossier with product description and intended use, technical details (design, materials, performance claims), and global regulatory status (approvals in US, EU, etc.). CDSCO reviews and provides written confirmation of the classification. Thus, the pre-filing consultation facility helps applicants receive clarity on whether their device is Class A, B, C, or D. This ensures correct fees, documentation, and timelines when filing the actual application.
Benefits
- Reduces risk: Avoids rejection of the CDSCO medical device application due to wrong classification.
- Saves time: Prevents back-and-forth queries during formal submission.
- Improves compliance: Ensures alignment with CDSCO’s expectations from the start.
- Supports SMEs: Especially valuable for smaller manufacturers unfamiliar with India’s regulatory nuances.
Limitations
- The pre-filing consultation facility is not available for in vitro diagnostics (IVDs).
- It does not replace the need for complete technical documentation during the actual submission.
- It provides classification guidance only and not a guarantee of CDSCO medical device license approval.
Thus, the pre-filing consultation facility helps companies start on the right regulatory track. Additionally, it helps save time and resources while aligning with CDSCO’s stricter compliance timelines.
Implications of the 90-day SUGAM portal application rejection rule for applicants
- Higher compliance pressure: Companies must respond to regulatory queries within strict timelines or risk automatic rejection. This forces tighter internal monitoring and faster turnaround.
- Operational discipline: Regulatory teams need robust tracking systems to ensure no query slips through. Missed reminders can mean losing months of effort and fees.
- Audit readiness: Documentation must be complete and accurate from the start to minimize back‑and‑forth with CDSCO. Poorly prepared submissions will face rejection more quickly.
- Strategic advantage: Using the pre‑filing consultation facility can prevent misclassification issues, thereby saving time and avoiding disputes over device categories.
- Impact on backlog: Long‑pending applications (some over 2 years old) will be cleared out, meaning only active, responsive applicants remain in the system.
- Commercial risk: Delays or rejections can postpone product launches, affect market entry, and disrupt business plans.
How should companies prepare?
- Set up internal tracking systems for SUGAM portal queries.
- Respond promptly to CDSCO reminders (within the 90-day window).
- Leverage pre-filing consultations to avoid medical device classification disputes.
- Ensure documentation accuracy to minimize back-and-forth with regulators.
Thus, CDSCO has introduced the new 90-day SUGAM portal application rejection rule aimed at clearing a massive backlog of submissions, some pending for nearly a decade. We at Pharmadocx Consultants provide comprehensive CDSCO license application service. Our service covers CDSCO query response. Our team will help you respond to the CDSCO queries accurately and in a timely manner. Drop an email at [email protected] or call/Whatsapp on 9996859227 to avail our exclusive CDSCO query response service.
FAQs
What is the SUGAM portal?
SUGAM is the official CDSCO online portal used for submitting and tracking drug, medical device, IVD, and cosmetics license applications.
What is the new rule introduced for SUGAM application rejection?
CDSCO has introduced a new 90-day SUGAM portal application rejection rule.
What is the new pre-filing consultation facility?
The pre-filing consultation facility allows applicants to get confirmation on medical device class before applying for a license.
Is the pre-filing consultation facility free?
Yes, it is free of charge.
What is the deadline for old pending CDSCO medical device application queries?
CDSCO medical device applications pending for more than two years with three reminders being sent must be responded to by February 14, 2026, or else they will be rejected.
